Novo’s late-stage sickle cell win piles pressure on competitors
BioSpace
Novo Nordisk's etavopivat elicited a 27% drop in vaso-occlusive crises and 48.7% hemoglobin response after 24 weeks, creating "separation amongst PK class candidates," Truist analysts said on Monday.
pharminent
April 20, 2026 (Last updated: April 20, 2026)
BioSpace
Novo Nordisk’s etavopivat elicited a 27% drop in vaso-occlusive crises and 48.7% hemoglobin response after 24 weeks, creating “separation amongst PK class candidates,” Truist analysts said on Monday.
